Impact of biological/targeted versus conventional synthetic disease‐modifying antirheumatic drugs on patient‐reported outcomes in rheumatoid arthritis

Abstract Background In patients with rheumatoid arthritis (RA), patient‐reported outcomes (PROs) may vary by disease‐modifying antirheumatic drug (DMARD) class. This study aimed to assess the impact of biological/targeted synthetic DMARDs (b/tsDMARDs) on PROs in patients with sustained low RA activi...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Masafumi Sugiyama, Saki Okuda‐Tsuchimoto, Takashi Tsuchimoto, Koji Kinoshita, Itaru Matsumura
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Wiley 2026-06-01
Edice:	Rheumatology & Autoimmunity
Témata:	b/tsDMARDs methotrexate patient‐reported outcomes rheumatoid arthritis
On-line přístup:	https://doi.org/10.1002/rai2.70048
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!